Jazz Pharmaceuticals (JAZZ) Common Equity (2010 - 2026)
Jazz Pharmaceuticals' quarterly Common Equity came in at $4.5 billion in Q1 2026, up 8.56% year-on-year from $4.2 billion in Q1 2025, and up 4.95% quarter-over-quarter from $4.3 billion in Q4 2025.
Jazz Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $4.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 8.56% year-over-year to $4.5 billion; the trailing twelve-month figure through Mar 2026 stood at $4.5 billion (up 8.56% YoY), and the FY2025 full-year result was $4.3 billion, up 5.49% from the prior year.
- Common Equity for Q1 2026 stood at $4.5 billion, up from $4.3 billion in the prior quarter.
- The five-year high for Common Equity was $4.5 billion in Q1 2026, with the low at $2.7 billion in Q3 2022.
- Average Common Equity over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2025.
- Year-over-year, Common Equity plunged 30.3% in 2022 and increased 27.11% in 2023.
- Tracing JAZZ's Common Equity over 5 years: stood at $3.1 billion in 2022, then grew by 21.11% to $3.7 billion in 2023, then grew by 9.55% to $4.1 billion in 2024, then rose by 5.49% to $4.3 billion in 2025, then climbed by 4.95% to $4.5 billion in 2026.
- The last three Common Equity figures came in at $4.5 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 4.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.53 Bn |
| Dec 31, 2025 | 4.32 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Jun 30, 2025 | 3.71 Bn |
| Mar 31, 2025 | 4.17 Bn |
| Dec 31, 2024 | 4.09 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Jun 30, 2024 | 3.76 Bn |
| Mar 31, 2024 | 3.70 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.49 Bn |
| Jun 30, 2023 | 3.53 Bn |
| Mar 31, 2023 | 3.34 Bn |
| Dec 31, 2022 | 3.09 Bn |
| Sep 30, 2022 | 2.75 Bn |
| Jun 30, 2022 | 3.20 Bn |
| Mar 31, 2022 | 3.61 Bn |
| Dec 31, 2021 | 3.97 Bn |
| Sep 30, 2021 | 3.94 Bn |
| Jun 30, 2021 | 4.13 Bn |
| Mar 31, 2021 | 3.80 Bn |
| Dec 31, 2020 | 3.66 Bn |
| Sep 30, 2020 | 3.38 Bn |
| Jun 30, 2020 | 3.14 Bn |
| Mar 31, 2020 | 2.81 Bn |
| Dec 31, 2019 | 3.11 Bn |
| Sep 30, 2019 | 3.05 Bn |
| Jun 30, 2019 | 2.98 Bn |
| Mar 31, 2019 | 2.73 Bn |
| Dec 31, 2018 | 2.76 Bn |
| Sep 30, 2018 | 3.03 Bn |
| Jun 30, 2018 | 2.87 Bn |
| Mar 31, 2018 | 2.79 Bn |
| Dec 31, 2017 | 2.71 Bn |
| Sep 30, 2017 | 2.47 Bn |
| Jun 30, 2017 | 2.20 Bn |
| Mar 31, 2017 | 1.98 Bn |
| Dec 31, 2016 | 1.88 Bn |
| Sep 30, 2016 | 1.83 Bn |
| Jun 30, 2016 | 1.80 Bn |
| Mar 31, 2016 | 1.71 Bn |
| Dec 31, 2015 | 1.71 Bn |
| Sep 30, 2015 | 1.56 Bn |
| Jun 30, 2015 | 1.45 Bn |
| Mar 31, 2015 | 1.31 Bn |
| Dec 31, 2014 | 1.37 Bn |
| Sep 30, 2014 | 1.34 Bn |
| Jun 30, 2014 | 1.28 Bn |
| Mar 31, 2014 | 1.27 Bn |
| Dec 31, 2013 | 1.30 Bn |
| Sep 30, 2013 | 1.24 Bn |
| Jun 30, 2013 | 1.18 Bn |
| Mar 31, 2013 | 1.16 Bn |
| Dec 31, 2012 | 1.12 Bn |
| Sep 30, 2012 | 886.09 Mn |
| Jun 30, 2012 | 831.46 Mn |
| Mar 31, 2012 | 781.83 Mn |
| Dec 31, 2011 | 192.79 Mn |
| Sep 30, 2011 | 141.33 Mn |
| Jun 30, 2011 | 101.60 Mn |
| Dec 31, 2010 | 30.55 Mn |